UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

   
 
 

 

     
     

 

(Check one):   x  Form 10-K   o  Form 20-F   o  Form 11-K   o  Form 10-Q   o  Form 10-D
    o  Form N-SAR   o  Form N-CSR            
                     
    For Period Ended: December 31, 2013
    o  Transition Report on Form 10-K        
    o  Transition Report on Form 20-F        
    o  Transition Report on Form 11-K        
    o  Transition Report on Form 10-Q        
    o  Transition Report on Form N-SAR        
    For the Transition Period Ended:  
                       

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

 

 

 

PART I — REGISTRANT INFORMATION

 

 Oncovista Innovative Therapies, Inc.

Full Name of Registrant
 
 
Former Name if Applicable
 

14785 Omicron Drive, Ste 104

Address of Principal Executive Office (Street and Number)
 

San Antonio, TX, 78245

City, State and Zip Code

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

o (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
o (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 
 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Company is in the final stages of the auditing process. However, the first draft of the 10-K was not received from our auditing firm as of today. In order to be on the safe side, Oncovista Innovative Therapies, Inc. is filing extension Form 12b-25. The Company expects to file Form 10-K on or before the fifteenth calendar day following the original due date.

  

 

PART IV — OTHER INFORMATION

 

(1)   Name and telephone number of person to contact in regard to this notification
    Alexander L. Weis   210   863-6813
    (Name)   (Area Code)   (Telephone Number)
     
(2)   Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).
     
            x  Yes     o  No
             
(3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
     
            o  Yes     x  No
             
   

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

 

 

 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date March 28, 2014   By /s/ Alexander L. Weis
        Alexander L. Weis
         

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

  ATTENTION  
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

OncoVista Innovative The... (CE) (USOTC:OVIT)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more OncoVista Innovative The... (CE) Charts.
OncoVista Innovative The... (CE) (USOTC:OVIT)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more OncoVista Innovative The... (CE) Charts.